pipette
ESEspañol

Focused ultrasound-enhanced carboplatin delivery improves radiotherapy response and survival in a preclinical glioblastoma model

S. Rigollet, S. Keshmiri, S. Dbira, M. D'allemagne, T. Ador, A. Leboucher, V. Stupar, B. Lemasson, A. Delalande, J.-F. Adam, A.-L. Bulin, B. Chovelon, E. Dumont, J.-L. Ravanat, E. Barbier, H. Elleaume

PreprintReal-world use

In the authors' words

Rationale Glioblastoma is highly resistant to conventional therapies due to the limited penetration of chemotherapeutics across the blood-brain and blood-tumor barriers (BBB, BTB). Although platinum-based drugs show strong cytotoxic and radiosensitizing properties in several cancers, their inability to achieve therapeutic concentrations within the central nervous system (CNS) severely limits their efficacy in brain tumors. This study investigated whether focused ultrasound (FUS)-mediated BBB/BTB disruption combined with intravenous carboplatin and stereotactic radiotherapy could improve drug delivery, tumor control, and survival in a preclinical glioblastoma model. Methods F98 glioma-bearing rats were treated with a single dose of 15 Gy radiation therapy (RT), carboplatin only, carboplatin + RT, FUS + carboplatin or FUS + carboplatin + RT. FUS-mediated permeabilization was confirmed by magnetic resonance imaging (MRI), and platinum accumulation was quantified by inductively coupled plasma mass spectrometry and synchrotron X-ray fluorescence. Tumor progression and microenvironmental changes were monitored using multiparametric MRI (diffusion, perfusion, and vascular permeability), followed by voxel-wise clustering analysis and histopathological validation. Results The FUS + carboplatin + RT group demonstrated the strongest therapeutic benefit, compared to all other treatment groups, yielding up to a 122% increase in median survival relative to the untreated group. This treatment also reduced necrotic core expansion and induced a transient increase in tumor perfusion, suggesting improved vascular function. FUS enhanced carboplatin delivery to both the tumor and peritumoral brain, with platinum distribution closely correlating with MRI signal enhancement. Voxel-wise clustering of multiparametric MRI identified biologically distinct tumor regions that were subsequently validated by immunohistochemistry. Conclusion The combination of FUS-mediated carboplatin delivery and radiotherapy represents a safe, non-invasive strategy that enhances drug delivery and improves survival in an aggressive preclinical model of glioblastoma. By overcoming a major limitation of current therapies, this approach shows promising potential for clinical translation. Keywords Glioblastoma, Focused Ultrasound, Blood-Brain Barrier, Chemotherapy, Radiotherapy

Main resultThe abstract does not state a limitation.

Appeared: Wednesday, November 18. bioRxiv. Preprint, not yet peer-reviewed.

DOI: 10.64898/2026.11.17.766937